Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Annals of the Rheumatic Diseases · 2013 · 2.9K citations

Medicine, Clinical Sciences, Internal Medicine +15

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Changes in causes of death in systemic sclerosis, 1972–2002

V. Steen, Thomas A. Medsger · Annals of the Rheumatic Diseases · 2007 · 1.5K citations · Full text

Medicine, Cardiology, Immunopathology +7

Interstitial Lung Disease in Systemic Sclerosis

Nicole Goh, Sujal R. Desai, Srihari Veeraraghavan et al. · American Journal of Respiratory and Critical Care Medicine · 2008 · 1.2K citations

Medicine, Clinical Sciences, Internal Medicine +17

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations

Medicine, Pharmacology, Pharmacotherapy +11